Cancer cells are characterized in general by a decrease of mitochondrial respiration and OXPHOS, a consequence of disruptive mtDNA mutations, thus one might affirm that the growth of cancer cells is directly limited by cellular energetics. In order to survive, cancer cells must modify their mitochondrial physiology to optimize energy production towards their changing environments. There are two types of advantageous mtDNA mutations for cancer cells: mutations that impair OXPHOS and serve to stimulate neoplastic transformation, and those that facilitate cancer cell adaptation to altered bioenergetics environment. These mtDNA mutations would eventually lead to an enhanced generation of reactive oxygen species (ROS), which acts both as mutagens and cellular mitogens, and contribute directly to cancer progression. Therefore, it can be concluded that mitochondrial alterations are critical for cancer initiation, promotion, and metastasis (Fig 1) .
Top three arrows: factors that have impact on mitochondrial OXPHOS robustness, risk for developing disease symptoms. Central oval arrows: pathophysiological basis of disease processes and the basis of disease progression. Lower five arrows: summarized disease categories and phenotypic outcomes of disturbed mitochondrial energy transformation. Bottom arrow: effect of the problematic accumulation of somatic mtDNA mutations resulting in delayed-onset and progressive course of diseases and aging. Right arrow: clinical problems that can result from reduced energy production in the most energetic tissues: the brain, heart, muscle, and kidney. Left arrow: indicates the metabolic effects of mitochondrial dysfunction, which result in the perturbation of the body's energy balance. Lower right arrow: mitochondrial alterations are critical for cancer initiation, promotion, and metastasis. Lower left arrow: the hypothesized inflammatory and autoimmune responses that may result from chronic introduction of mitochondria's bacterialike DNA and N-formylmethionine proteins into the bloodstream. FIGURE 1. Integrated mitochondrial paradigm explaining genetic and phenotypic complexities of metabolic and degenerative disease, aging, and cancer.
